Survivors of pediatric retinoblastoma have few cognitive and social problems during adulthood
the ONA take:
According to a new study published online in the journal Cancer, researchers have found that adults who survived childhood retinoblastoma have limited cognitive and social issues later in life.
For the study, researchers at St. Jude Children's Research Hospital in Memphis, Tennessee, sought to investigate the long-term health issues of survivors of the eye cancer following diagnosis and treatment. Although most children are cured of the disease, survivors have a higher risk of long-term health effects from intensive treatments.
The researchers identified 69 adult survivors of childhood retinoblastoma who were 33 years old on average and were treated for the treated an average of 31 years earlier. Participants then completed cognitive evaluations and questionnaires.
Results showed that survivors had few cognitive and social problems. In addition, researchers found that patients who received whole brain radiation treatment had a poorer performance on short-term and long-term verbal memory tasks.
They also found that survivors who were diagnosed before age 1 had a significantly better performance on short-term and long-term verbal memory tasks, verbal learning tasks, and verbal reasoning measures compared with those diagnosed after age 1. The researchers suggest that the brain is able to adapt and reorganize following early treatment.
Adults who survived childhood retinoblastoma have limited cognitive and social issues later in life.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|